CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

40th Annual CFS® Highlights New Frontiers in Cancer Care

November 9th 2022

The Chemotherapy Foundation Symposium® returns to New York City for its 40th annual meeting with a 3-day program that will deliver the latest updates across the gamut of oncology care.

CAR T-Cell Therapies Improve Treatment Landscape in Relapsed/Refractory Multiple Myeloma

November 8th 2022

The increasing integration of CAR T-cell therapies into the treatment paradigm for adult patients with relapsed or refractory multiple myeloma addresses several unmet needs and improves outcomes for this historically limited patient population.

Dr. Ramakrishnan on Advancements With CAR T-cell Therapies in LBCL

November 4th 2022

Praveen Ramakrishnan, MD, MS, discusses the clinical implications of CAR T-cell therapy in large B-cell lymphoma.

Dr. Ramakrishnan on Negative Results of the BELINDA Trial in Non-Hodgkin Lymphoma

November 3rd 2022

Praveen Ramakrishnan, MD, discusses the negative results from the phase 3 BELINDA trial and its effect on the use of CAR T-cell products in aggressive B-cell non-Hodgkin lymphoma.

Dr. Hill and Dr. Sauter Consider CAR T-Cell Therapy in Second-Line Setting for DLBCL

November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, consider CAR T-cell therapy in the second-line setting for patients with diffuse large B-cell lymphoma.

Cleveland Clinic Experts Assess Strategies to Accelerate CAR T-Cell Production

November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss recent data showing that the CAR T-cell production can be shortened.

Dr. Hill and Dr. Sauter Discuss the Future of CAR T-Cell Products Agents in Lymphoma

November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss potential directions for CAR T-cell therapy in lymphomas.

Cleveland Clinic Experts Discuss the Potential for Allogeneic CAR T-Cell Agents

November 2nd 2022

Brian T. Hill, MD, PhD, and Craig Sauter, MD, discuss the promise of allogeneic CAR T-cell products.

Dr. Hill and Dr. Sauter Address Financial Toxicity in CAR T-Cell Therapy

November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, address the issue of financial toxicity in CAR T-cell therapy.

Dr. Romancik on the Phase 2 PILOT Study of Liso-Cel in Aggressive B-Cell NHL

November 1st 2022

Jason Romancik, MD, discusses the design and key results from the phase 2 PILOT study.

Cilta-cel Induces Strong Response in Chinese Patients With Relapsed/Refractory Multiple Myeloma

October 28th 2022

Ciltacabtagene autoleucel produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma treated at 8 sites in China.

European Commission Approves Second-line Axi-cel for DLBCL/HGBL

October 18th 2022

The European Commission has approved axicabtagene ciloleucel for the treatment of adult patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Novel ADC and CAR T Approaches Broaden the DLBCL Treatment Landscape

October 17th 2022

Praveen Ramakrishnan, MD, MS, discusses the evolution of diffuse large B-cell lymphoma treatment, the implications of key phase 3 studies, and how emerging bispecific T-cell engagers and antibody-drug conjugates may increase treatment accessibility beyond the limitations of CAR T-cell therapy for patients at various disease stages.

CAR T-cell Therapy CYAD-101 No Longer Under Development for Metastatic CRC

October 14th 2022

Celyad Oncology has discontinued development its investigational CAR T-cell therapy CYAD-101 for the treatment of patients with unresectable metastatic colorectal cancer.

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Dr Brentjens discussed targeting the “enigmatic” GPRC5D protein, safety results with MCARH109, and the appropriate sequencing for the agent.

GPRC5D Antigen–Targeted CAR T-cell Therapy Induces Strong Response in Resistant Multiple Myeloma

October 3rd 2022

MCARH109, a CAR T-cell therapy targeting the “enigmatic” GPRC5D antigen, generated remissions in 70.6% of patients with relapsed/refractory multiple myeloma.

FDA Grants Orphan Drug Designation to SynKIR-110 for Mesothelin-Expressing Mesothelioma

September 28th 2022

The FDA has granted an orphan drug designation to SynKIR-110, a first-in-class KIR-CAR T-cell immunotherapy candidate, for the treatment of patients with mesothelin-expressing mesothelioma.

Gavo-cel Elicits Clinical Benefit in Solid Tumors, Including Ovarian Cancer and Mesothelioma

September 28th 2022

Gavocabtagene autoleucel demonstrated positive topline results from the phase 1 portion of a phase 1/2 trial in patients with mesothelin-expressing solid tumors.

Dr. Paul on the Management of CRS and ICANS After CAR T-cell Therapy in Cancer Care

September 27th 2022

Barry Paul, MD, discusses the management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome following CAR T-cell therapy in cancer care.

Zevor-cel Elicits 100% ORR in Heavily Pretreated Relapsed/Refractory Myeloma

September 22nd 2022

The BCMA-directed CAR T-cell therapy zevorcabtagene autoleucel demonstrated a 100% objective response rate in heavily pretreated patients with relapsed/refractory multiple myeloma